Constant estrogen, intermittent progestogen vs. continuous combined hormone replacement therapy: Tolerability and effect on vasomotor symptoms

International Journal of Gynecology and Obstetrics

Volumn 72, Issue 3, 2001, Pages 235-243

  Rozenberg, S ^a   Caubel, P ^b   Lim, P C ^b  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

17 estradiol; Estrogen; Hormone replacement therapy; Norethisterone acetate; Norgestimate; Progestogen

Indexed keywords

ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTROGEN; GESTAGEN; NORETHISTERONE ACETATE; NORGESTIMATE; PREFEST; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG TOLERABILITY; EDEMA; FEMALE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; MASTALGIA; MULTICENTER STUDY; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UTERUS BLEEDING; VASOMOTOR REFLEX;

EID: 0035131585     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7292(00)00342-8     Document Type: Article

References (33)

1. Long-term hormone replacement treatment in menopause: new choices, old apprehensions, recent findings
2. Benefits and risks of hormone replacement therapy (HRT)
3. Current concepts in estrogen replacement therapy in the menopause
4. The prevention and treatment of osteoporosis
5. Use of low-dosage 17 beta-estradiol for the prevention of osteoporosis
6. Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study
7. Long-term estrogen replacement therapy prevents bone loss and fractures
8. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial
9. Oral contraceptive use and risk of colorectal cancer
10. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women
11. The biology of estrogen-mediated repair of cardiovascular injury
12. Vascular aspects of oestrogen
13. Alzheimer's disease: an estrogen link?
14. Estrogen and cognitive functioning in women
15. Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks
16. Estrogen improves psychological function in asymptornatic postmenopausal women
17. Replacement estrogens and endometrial cancer
18. Endometrial cancer and hormone replacement therapy. Appropriate use of progestins to oppose endogenous and exogenous estrogen
19. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium
20. The effects of oestrogens and progestogens on the postmenopausal endometrium
21. Hormone replacement therapy: aspects of bleeding problems and compliance
22. Progestogen intolerance and compliance with hormone replacement therapy in menopausal women
23. Women's concerns with hormone replacement therapy - compliance issues
24. Regulation of estrogen/progestogen receptors in the endometrium
25. Human endometrial cells in primary tissue culture: modulation of the progesterone receptor level by natural and synthetic estrogens in vitro
26. Regulation of estrogen receptor replenishment by progesterone
27. Cytoplasmic and nuclear estradiol and progesterone receptors in human endometrium
28. Effect of a unique constant-estrogen, pulsed-progestin hormone replacement therapy containing 17β-estradiol and norgestimate on endometrial histology
29. A novel intermittent regimen of norgestimate to preserve the beneficial effects of 17β-estradiol on lipid and lipoprotein profiles
30. Efficacy and safety of a constant-estrogen, pulsed progestin regimen in hormone replacement therapy
31. Selectivity and minimal androgenicity of norgestimate in monophasic and triphasic oral contraceptives
32. Endometrial effects of a 1-year pulsed progestogen, constant estrogen hormone replacement therapy regimen, Prefest™
33. Effects on serum lipid profiles of continuous 17β-estradiol, intermittent norgestimate regimens versus continuous combined 17β-estradiol/norethisterone acetate hormone replacement therapy